POLYMER COULD KEEP SOLDIERS FROM BLEEDING TO DEATH
Mar201525

Many soldiers who are injured on the battlefield die from uncontrolled bleeding before ever reaching a surgical hospital.

In some cases, there’s not much medics can do—a tourniquet won’t stop bleeding from a chest wound, and clotting treatments that require refrigerated or frozen blood products aren’t always available in the field.

Administered by a simple shot, a new polymer finds any unseen or internal injuries and starts working immediately to strengthen blood clots. The material could become a first line of defense in battlefield injuries, rural car accidents, and search and rescue missions deep in the mountains.

KEEP PEOPLE ALIVE

In an initial study with rats, 100 percent of animals injected with the material, called PolySTAT, survived a typically-lethal injury to the femoral artery. Only 20 percent of rats treated with a natural protein that helps blood clot survived.

“Most of the patients who die from bleeding die quickly,” says Nathan White, assistant professor of emergency medicine at University of Washington and coauthor of the study in Science Translational Medicine.

“This is something you could potentially put in a syringe inside a backpack and give right away to reduce blood loss and keep people alive long enough to make it to medical care.”

To develop the macromaterial, researchers were inspired by factor XIII, a natural protein found in the body that helps strengthen blood clots. Normally after an injury, platelets in the blood begin to congregate at the wound and form an initial barrier. Then a network of specialized fibers—called fibrin—start weaving themselves throughout the clot to reinforce it.

STRONGER CROSS-LINKS

If that scaffolding can’t withstand the pressure of blood pushing against it, the clot breaks apart and the patient keeps bleeding.

Both PolySTAT and factor XIII strengthen clots by binding fibrin strands together and adding “cross-links” that reinforce the latticework of that natural bandage.

“It’s like the difference between twisting two ropes together and weaving a net,” says coauthor Suzie Pun, professor of bioengineering. “The cross-linked net is much stronger.”

But the synthetic PolySTAT offers greater protection against natural enzymes that dissolve blood clots. Those help during the healing process, but they work against doctors trying to keep patients from bleeding to death.

The enzymes, which cut fibrin strands, don’t target the synthetic PolySTAT bonds that are now integrated into the clot. That helps keep the blood clots intact in the critical hours after an injury.

ROBUST CLOTS

“We were really testing how robust the clots were that formed,” says lead author Leslie Chan, doctoral student in bioengineering. “The animals injected with PolySTAT bled much less, and 100 percent of them lived.”

The synthetic polymer offers other advantages over conventional hemorrhaging treatments, White says. Blood products are expensive, need careful storage, and they can grow bacteria or carry infectious diseases. Plus, the hundreds of proteins introduced into a patient’s body during a transfusion can have unintended consequences.

After a traumatic injury, the body also begins to lose a protein that’s critical to forming fibrin. Once those levels drop below a certain threshold, existing treatments stop working and patients are more likely to die. PolySTAT works to strengthen clots even in cases where fibrin building blocks are critically low.

Researchers used a highly specific peptide that only binds to fibrin at the wound site. It doesn’t bind to a precursor of fibrin that circulates throughout the body. That means PolySTAT shouldn’t form dangerous clots that can lead to a stroke or embolism.

Though the polymer’s initial safety profile looks promising, next steps include testing on larger animals and additional screening to find out if it binds to any other unintended substances. Researchers also plan to investigate its potential for treating hemophilia and for integration into bandages.

The polymer could reach human trials in five years.

The National Institutes of Health, the UW Institute of Translational Health Sciences, the Washington Research Foundation, the National Institutes of Health, and private donations funded the work.

Leave a Comment